July 21, 2017 01:32 PM EDT
R&D

Bay­er’s block­buster pipeline promis­es bro­ken by a PhII set­back for top can­cer drug

John Carroll

Editor & Founder

Bay­er tout­ed its ex­per­i­men­tal can­cer drug ane­tum­ab rav­tan­sine as a $2 bil­lion-plus peak earn­er in the mak­ing for the phar­ma com­pa­ny. And it just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astel­las shakes up man­age­ment de­spite im­pres­sive nine-month earn­ings

Il­lu­mi­na added to Chi­na's black­list fol­low­ing Biose­cure Act, tar­iffs

A service from the Financial Times